Resveratrol does not benefit patients with nonalcoholic fatty liver disease

Veronique S Chachay; Graeme A Macdonald; Jennifer H Martin; Jonathan P Whitehead; Trisha M O'Moore--Sullivan; Paul Lee; Michael Franklin; Kerenaftali Klein; Paul J Taylor; Maree Ferguson; Jeff Coombes; Gethin Thomas; Gary J. Cowin; Carl Kirkpatrick; Johannes B Prins; Ingrid Hickman

doi:10.1016/j.cgh.2014.02.024

Resveratrol does not benefit patients with nonalcoholic fatty liver disease

Veronique S Chachay, Graeme A Macdonald, Jennifer H Martin, Jonathan P Whitehead, Trisha M O'Moore--Sullivan, Paul Lee, Michael Franklin, Kerenaftali Klein, Paul J Taylor, Maree Ferguson, Jeff Coombes, Gethin Thomas, Gary J. Cowin, Carl Kirkpatrick, Johannes B Prins, Ingrid Hickman

Research output: Contribution to journal › Article › peer-review

258 Citations (Scopus)

Abstract

Nonalcoholic fatty liver disease (NAFLD), characterized by accumulation of hepatic triglycerides (steatosis), is associated with abdominal obesity, insulin resistance, and inflammation. Although weight loss via calorie restriction reduces features of NAFLD, there is no pharmacologic therapy. Resveratrol is a polyphenol that prevents high-energy diet-induced steatosis and insulin resistance in animals by up-regulating pathways that regulate energy metabolism. We performed a placebo-controlled trial to assess the effects of resveratrol in patients with NAFLD.

Original language	English
Pages (from-to)	2092-2103.e6
Number of pages	18
Journal	Clinical Gastroenterology and Hepatology
Volume	12
Issue number	12
DOIs	https://doi.org/10.1016/j.cgh.2014.02.024
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cgh.2014.02.024

Cite this

Chachay, V. S., Macdonald, G. A., Martin, J. H., Whitehead, J. P., O'Moore--Sullivan, T. M., Lee, P., Franklin, M., Klein, K., Taylor, P. J., Ferguson, M., Coombes, J., Thomas, G., Cowin, G. J., Kirkpatrick, C., Prins, J. B., & Hickman, I. (2014). Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology, 12(12), 2092-2103.e6. https://doi.org/10.1016/j.cgh.2014.02.024

@article{ccba73e378bb453bbe7fde329a61b211,

title = "Resveratrol does not benefit patients with nonalcoholic fatty liver disease",

abstract = "Nonalcoholic fatty liver disease (NAFLD), characterized by accumulation of hepatic triglycerides (steatosis), is associated with abdominal obesity, insulin resistance, and inflammation. Although weight loss via calorie restriction reduces features of NAFLD, there is no pharmacologic therapy. Resveratrol is a polyphenol that prevents high-energy diet-induced steatosis and insulin resistance in animals by up-regulating pathways that regulate energy metabolism. We performed a placebo-controlled trial to assess the effects of resveratrol in patients with NAFLD.",

keywords = "NAFLD, Obesity-related fatty liver, Chronic disease, ALT, AST",

author = "Chachay, {Veronique S} and Macdonald, {Graeme A} and Martin, {Jennifer H} and Whitehead, {Jonathan P} and O'Moore--Sullivan, {Trisha M} and Paul Lee and Michael Franklin and Kerenaftali Klein and Taylor, {Paul J} and Maree Ferguson and Jeff Coombes and Gethin Thomas and Cowin, {Gary J.} and Carl Kirkpatrick and Prins, {Johannes B} and Ingrid Hickman",

note = "Includes bibliographical references.",

year = "2014",

doi = "10.1016/j.cgh.2014.02.024",

language = "English",

volume = "12",

pages = "2092--2103.e6",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders",

number = "12",

}

Chachay, VS, Macdonald, GA, Martin, JH, Whitehead, JP, O'Moore--Sullivan, TM, Lee, P, Franklin, M, Klein, K, Taylor, PJ, Ferguson, M, Coombes, J, Thomas, G, Cowin, GJ, Kirkpatrick, C, Prins, JB & Hickman, I 2014, 'Resveratrol does not benefit patients with nonalcoholic fatty liver disease', Clinical Gastroenterology and Hepatology, vol. 12, no. 12, pp. 2092-2103.e6. https://doi.org/10.1016/j.cgh.2014.02.024

TY - JOUR

T1 - Resveratrol does not benefit patients with nonalcoholic fatty liver disease

AU - Chachay, Veronique S

AU - Macdonald, Graeme A

AU - Martin, Jennifer H

AU - Whitehead, Jonathan P

AU - O'Moore--Sullivan, Trisha M

AU - Lee, Paul

AU - Franklin, Michael

AU - Klein, Kerenaftali

AU - Taylor, Paul J

AU - Ferguson, Maree

AU - Coombes, Jeff

AU - Thomas, Gethin

AU - Cowin, Gary J.

AU - Kirkpatrick, Carl

AU - Prins, Johannes B

AU - Hickman, Ingrid

N1 - Includes bibliographical references.

PY - 2014

Y1 - 2014

N2 - Nonalcoholic fatty liver disease (NAFLD), characterized by accumulation of hepatic triglycerides (steatosis), is associated with abdominal obesity, insulin resistance, and inflammation. Although weight loss via calorie restriction reduces features of NAFLD, there is no pharmacologic therapy. Resveratrol is a polyphenol that prevents high-energy diet-induced steatosis and insulin resistance in animals by up-regulating pathways that regulate energy metabolism. We performed a placebo-controlled trial to assess the effects of resveratrol in patients with NAFLD.

AB - Nonalcoholic fatty liver disease (NAFLD), characterized by accumulation of hepatic triglycerides (steatosis), is associated with abdominal obesity, insulin resistance, and inflammation. Although weight loss via calorie restriction reduces features of NAFLD, there is no pharmacologic therapy. Resveratrol is a polyphenol that prevents high-energy diet-induced steatosis and insulin resistance in animals by up-regulating pathways that regulate energy metabolism. We performed a placebo-controlled trial to assess the effects of resveratrol in patients with NAFLD.

KW - NAFLD

KW - Obesity-related fatty liver

KW - Chronic disease

KW - ALT

KW - AST

U2 - 10.1016/j.cgh.2014.02.024

DO - 10.1016/j.cgh.2014.02.024

M3 - Article

C2 - 24582567

SN - 1542-3565

VL - 12

SP - 2092-2103.e6

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 12

ER -

Resveratrol does not benefit patients with nonalcoholic fatty liver disease

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this